Journal of Experimental & Clinical Cancer Research (Oct 2023)

Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential

  • Emilia Alors-Pérez,
  • Sergio Pedraza-Arevalo,
  • Ricardo Blázquez-Encinas,
  • María Trinidad Moreno-Montilla,
  • Víctor García-Vioque,
  • Inmaculada Berbel,
  • Raúl M. Luque,
  • Bruno Sainz,
  • Alejandro Ibáñez-Costa,
  • Justo P. Castaño

DOI
https://doi.org/10.1186/s13046-023-02858-z
Journal volume & issue
Vol. 42, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers worldwide, mainly due to its late diagnosis and lack of effective therapies, translating into a low 5-year 12% survival rate, despite extensive clinical efforts to improve outcomes. International cooperative studies have provided informative multiomic landscapes of PDAC, but translation of these discoveries into clinical advances are lagging. Likewise, early diagnosis biomarkers and new therapeutic tools are sorely needed to tackle this cancer. The study of poorly explored molecular processes, such as splicing, can provide new tools in this regard. Alternative splicing of pre-RNA allows the generation of multiple RNA variants from a single gene and thereby contributes to fundamental biological processes by finely tuning gene expression. However, alterations in alternative splicing are linked to many diseases, and particularly to cancer, where it can contribute to tumor initiation, progression, metastasis and drug resistance. Splicing defects are increasingly being associated with PDAC, including both mutations or dysregulation of components of the splicing machinery and associated factors, and altered expression of specific relevant gene variants. Such disruptions can be a key element enhancing pancreatic tumor progression or metastasis, while they can also provide suitable tools to identify potential candidate biomarkers and discover new actionable targets. In this review, we aimed to summarize the current information about dysregulation of splicing-related elements and aberrant splicing isoforms in PDAC, and to describe their relationship with the development, progression and/or aggressiveness of this dismal cancer, as well as their potential as therapeutic tools and targets.

Keywords